Maze Therapeutics, Inc. (MAZE) Stock Statistics & Valuation Metrics

Maze Therapeutics, Inc. has a market cap or net worth of $1.48B. The enterprise value is $1.31B.

Maze Therapeutics, Inc. has 49,708,656 shares outstanding. The number of shares has decreased by -2.65% in one year.

Maze Therapeutics, Inc.’s return on equity (ROE) is -0.37 and return on invested capital (ROIC) is -37.67%.

The current PE Ratio of Maze Therapeutics, Inc. is ―. Maze Therapeutics, Inc.’s PEG ratio is 0.00338.

In the last 12 months, Maze Therapeutics, Inc. had revenue of 0.00 and earned -131.12M in profits. Earnings per share was -3.05.

In the last 12 months, operating cash flow was -111.94M and capital expenditures -794.00K, giving a free cash flow of -112.73M billion.

Maze Therapeutics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

Maze Therapeutics, Inc. upcoming earnings date is Apr 6, 2026, Before Open (Confirmed).

Maze Therapeutics, Inc. as a current ratio of 15.50, with Debt / Equity ratio of 6.57%

In the past 12 months, Maze Therapeutics, Inc. has paid 0.00 in taxes.

Maze Therapeutics, Inc. EV to EBITDA ratio is -11.49, with an EV/FCF ratio of -14.32.

Maze Therapeutics, Inc. has $341.92M in cash and marketable securities with $23.31M in debt, giving a net cash position of $318.61M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Maze Therapeutics, Inc. is $65.56, which is 11.43% higher than the current price. The consensus rating is Strong Buy